<DOC>
	<DOCNO>NCT00026104</DOCNO>
	<brief_summary>Randomized phase II trial compare effectiveness gemcitabine , paclitaxel , radiation therapy without tipifarnib treat patient locally advanced pancreatic cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Tipifarnib may stop growth tumor cell block enzymes necessary tumor cell growth . Combining chemotherapy radiation therapy tipifarnib may effective treatment pancreatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy With Without Tipifarnib Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare 1-year survival rate patient locally advanced pancreatic cancer treat paclitaxel , gemcitabine , radiotherapy without tipifarnib . II . Determine toxicity loco-regional activity chemoradiotherapy regimen patient . III . Determine feasibility toxicity prolong administration tipifarnib chemoradiotherapy patient . IV . Determine whether tipifarnib administer chemoradiotherapy increase progression-free overall survival patient . OUTLINE : This randomize , multicenter study . Patients stratify accord weight loss precede 6 month ( 10 % vs 10 % less ) tumor dimension ( least 5 cm v le 5 cm ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive radiotherapy daily , 5 day week , 5.5 week , begin day 1 . Patients also receive paclitaxel IV 1 hour gemcitabine IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 . Arm II : Patients receive chemoradiotherapy arm I . Within 3-8 week completion chemoradiotherapy , patient without disease progression receive oral tipifarnib twice daily 21 day . Treatment continue every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm unresectable , locally advanced adenocarcinoma pancreas Residual disease resection ( R1 R2 , microscopic macroscopic ) allow No metastasis major viscera No peritoneal seed ascites Biliary gastroduodenal obstruction must drainage start study therapy Radiographically assessable disease encompassable within single irradiation field ( 15 15 cm maximum ) Performance status Zubrod 01 Granulocyte count least 1,800/mm^3 Platelet count least 100,000/mm^3 ALT less 3 time upper limit normal Bilirubin le 2.0 mg/dL Creatinine le 3.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix , uterus , bladder No significant infection medical condition would preclude study No prior chemotherapy ( include gemcitabine paclitaxel ) pancreatic cancer No concurrent cytotoxic agent See Disease Characteristics No prior radiotherapy plan field No concurrent radiotherapy See Disease Characteristics No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>